Since the publication of an oestrogen receptor (ER) cDNA sequence from the breast cancer cell line MCF-7 (Green et al., 1986) it has been acknowledged that ER is encoded by a single gene. However, there is evidence that the ER protein itself is heterogeneous (Jensen et al., 1971; Wittliff et al., 1972; Puddefoot et al., 1987) . Using sucrose density gradient centrifugation, the ER obtained in the soluble fractions is recovered either as a large 8S complex or as a smaller 4S form. Other more sensitive techniques such as isoelectric focusing (IEF) (Wrange et aL, 1985; Bailleul et al., 1988a,b) , high performance liquid chromatography (HPLC) (Hutchens et al., 1982; Hutchens et al., 1983; Wielhe et al., 1984) and DEAE-cellulose chromatography (Wittliff, 1984) have also shown the ER to be present in various molecular forms.
Previous work from this laboratory using high resolution isoelectric focusing (IEF) and immunoblotting have shown that the 4S ER can be resolved into three components with isoelectric point (pI) values of 6.3, 6.6 and 6.8 while the 8S ER focuses as a single isoform at pl 6.1 (Marsigliante et al., 1991a) . Furthermore, IEF indicated that all of these isoforms bind oestradiol, diethylstilboestrol (DES) and tamoxifen (Marsigliante et al., 199 lb) .
One important function of the oestrogen receptor is its involvement in the oestrogenic induction of the progesterone receptor (PgR) which has been demonstrated at the levels of protein and mRNA in many tissues (Milgrom et al., 1973; Vu Hai et al., 1977; Mester & Baulieu, 1977; Horwitz & McGuire, 1978; Read et al., 1988; Alexander et al., 1989; Isomaa et al., 1979; May et al., 1989) . Furthermore, recent experiments involving site-directed mutagenesis strongly suggest that oestrogens induce the progesterone receptor gene through occupied ER binding to an oestrogen responsive element (ERE) present in the initiation region of the PgR gene (Savouret et al., 1991) .
The relationship between the ER and PgR content of breast tumours and response to endocrine therapy has been well documented although approximately 25% of patients whose tumours contain ER and PgR fail to respond (Wittliff, 1984) . It (McGuire et al., 1977; King et al., 1979; Puddefoot et al., 1987 Free hormone was separated from bound by incubation with DCC (0.5% (w/v) charcoal and 0.05% (w/v) dextran T70; BDH Chemicals Ltd., Poole, UK) at 4°C followed by centrifugation at 10,000 g for 5 min. An aliquot of the supernatant was counted in a liquid scintillation counter. A further aliquot of these samples was taken for IEF of ER.
Isoelectric focusing
The IEF gels were cast in slabs of size 125 x 260 mm and separation was conducted along either the short side (short run) or the long side (long run) of the gel. Polyacrylamide gels (2 mm thick), containing 20% (v/v) glycerol and with high porosity (T = 5%, C = 3%) were used. A pH gradient was achieved using 1.5% (w/v) LKB ampholine 3.5-10 (LKB, Bromma, Sweden) and 1.0% (w/v) LKB ampholine 5-8. Gels were photopolymerised at room temperature by means of a TR 26 polymerisation light (Hoefer S.I., San Francisco, USA), using riboflavin (0.004% v/v) for at least 8 h. IEF was performed in a cold room and the temperature of the cooling water was kept constant at 4°C using an LKB Multiphor II system with its chambers filled with 1 M NaOH to minimise CO2 absorption from the air. Electrode solutions of 1 M NaOH (cathode) and 1 M H2SO4 (anode) were used. Gels were pre-focused for 40 min at 20 mA/20 W/2000 V (long run) and for 40 min at 20 mA/20 W/1200 V (short run).
After DCC extraction, aliquots (270 jd) of the radioactive supernatants (3 mg protein/ml) derived from SSD assay were loaded near the cathode. The runs were carried out for 4 h using a 3000xi CC power supply (Bio-Rad, Hemel Hempstead, Herts, UK) at 2500 V/20 mA/20 W, constant power (long run) and at 1200 V/20 mA/20 W, constant power, for 1.5 h (short run). A mixture of nine natural proteins (BioRad) was used for pH calibration. After the run, the gels were cut into 2.5 mm slices and each slice was incubated with Results ER isoforms and their distribution in breast cancer tissues One hundred and five primary breast tumours were analysed for ER content, using the SSD method, of which 66 (63%) were ER-positive. These ER-positive tumours (ER concentrations ranging from 11 to 251 fmol/mg protein) were analysed by short and long run IEF. Short run gels showed only two radioactive peaks focusing at pI 6.1 and 6.6, which have previously been shown to represent the 8S and 4S forms of the ER respectively (Marsigliante et al., 1991b) . The higher resolution of long run IEF permitted the identification of two additional ER isoforms with pl values of 6.3 and 6.8 ( Figure  1 ). These are also found in rat uterus (data not shown). It was also possible to detect these 4 ER isoforms in tumours using immunoblotting of short run IEF separated ER (Marsigliante et al., 1991b) . Figure 2 shows four examples of ER profiles where one or more of the ER isoforms are missing.
Of the 66 ER-positive specimens examined, 64 (97.0%) contained the isoform at pI 6.6, 55 (83.3%) contained the isoform at pI 6.1, 26 (39.4%) contained the isoform at pl 6.3, and 22 (33.3%) contained the isoform at p16.8.
The ER isoform profiles of the 66 specimens examined by long run IEF are shown in Table I . Of particular interest is that only 8 out of the 66 samples (12.1%) contained the full complement of ER isoforms (pI6.1, 6.3, 6.6 and 6.8) and only 1 (1.5%) contained the all three 4S isoforms (pI 6.3, 6.6 and 6.8) in the absence of the 8S (pl 6.1) ER. It was also evident that no tumours contained the isoforms at pl 6.3 or 6.8 as a single isoform.
Correlation between ER isoforms and PgR levels in breast tumour samples Analysis of 43 ER-positive breast tumour cytosols was carried out using high resolution IEF and the ER and PgR Isoelectric focusing analysis (long run) of ER in the 100,000g supernatant from four different primary breast cancer tumours where one or more of the ER isoforms is missing. a, Tumour cytosol containing ER isoforms at isoelectric points (pI) 6.6 and 6.1 only (34.8% of tumours showed this profile). b, Tumour cytosol containing ER isoforms at pl 6.1, 6.3 and 6.6 (22.7% of tumours showed this profile). c, Tumour cytosol containing ER isoform at p1 6.6 only (12.1% of tumours showed this profile). d, Tumour cytosol containing ER isoforms at pl 6.3, 6.6 and 6.8 (only 1.5% of tumours showed this profile). Figure 3 . Statistical analysis on this data using Students' t-tests showed that tumours containing 3 or 4 ER isoforms appeared to have levels of PgR greater than 90 fmol/mg protein while those containing only 1 or 2 ER isoforms had significantly lower levels of PgR (P<0.001). The presence of the ER isoforms at pl 6.3 and pl 6.8 also appears to correlate with the presence of greater than 90 fmol PgR/mg protein (P <0.00l).
Discussion
Previous work using rat uterus (Jensen et al., 1967) and calf uterus (Puca et al., 1971; Sica et al., 1976) as sources of oestrogen receptor (ER) have shown that it exists as two distinct forms with sedimentation coefficients of 4S and 8S when studied using sucrose density gradient centrifugation. Previous work from this laboratory has shown that when these forms are subjected to IEF, the 8S has a pl value of 6.1 while the 4S is a composite of three separate isoforms with pl values of 6.3, 6.6 and 6.8 (Marsigliante et al., 1991b) .
Oestrogen receptors in human breast cancer samples have also been shown to express heterogeneity. Using DEAE chromatography, chromatofocusing, HPLC and IEF (Kute et al., 1978; Hutchens et al., 1983; Wielhe et al., 1984; Bailleul et al., 1988a,b) the ER in human breast tumours has also been shown to exist in several molecular forms. Using similar approaches to those described in this paper, we have shown that the ER from some breast tumour samples resolves into four ER isoforms (Marsigliante et al., 1991b) . These binding components represent subunits and not cleavage products (mero-receptors) due to proteolytic digestion of the ER (Jensen et al., 1967; Marsigliante et al., 1991b) and that they are all capable of binding oestradiol, tamoxifen and diethylstilboestrol (Marsigliante et al., 1991b represent the full complement (together with the 8S form) of the hormone-reactive ER. The distribution of the ER isoforms in the 66 ER-positive breast tumours analysed would suggest that the absence of the two 4S isoforms at pl 6.3 and 6.8 may be a feature of cancerous tissue since only 33.3% of tumours contained the pI 6.8 isoform and 39.4% contained the pI 6.3 isoform. In contrast 97.0% of tumours contained the 4S isoform at pI 6.6 and 83.3% contained the 8S (pI 6.1) isoform. Since our previous studies (Marsigliante et al., 1991b) have shown that all ER isoforms bind tamoxifen in vitro, the lack of these 4S ER isoforms at pI 6.3 and 6.8, could be important in response to endocrine treatment. An important function of the activated ER is its involvement in the oestrogenic induction of the progesterone receptor and the presence of PgR has been taken to reflect the activation of the PgR gene by oestrogen bound to its receptor. ER activation by oestrogen binding is thought to involve the formation of the nuclear dimeric form (Muller et al., 1983) and the ability to do this may require the formation of oligomeric complexes such as the 8S ER isoform. We have previously shown that the ability of the 4S ER to form the 8S assembly is an indicator of a fully functional receptor, in that PgR positivity is associated with the presence of the 8S oligomer (Marsigliante et al., 1990) . Data (McGuire & Clark, 1985) .
Apart from the existence of genetic variants of the ER gene which exist normally unassociated with tumourigenesis (Murphy 1990) , there is evidence supporting the presence of variant forms of ER mRNAs in human breast cancers. Garcia et al. (1988 Garcia et al. ( , 1989 
